Valuation: Lundbeck

Market Cap 4.15TCr 635.29Cr 555.37Cr 510.39Cr 475.74Cr 902.34Cr 60TCr 916.03Cr 6.13TCr 2.38TCr 30TCr 2.38TCr 2.33TCr 1,02500Cr P/E 2026 *
9.49x
P/E 2027 * 9.31x
Enterprise Value 4.56TCr 697.88Cr 610.09Cr 560.67Cr 522.61Cr 991.25Cr 66TCr 1.01TCr 6.73TCr 2.62TCr 33TCr 2.62TCr 2.56TCr 1,12600Cr EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.6x
Free-Float
30.76%
Yield 2026 *
3.42%
Yield 2027 * 3.53%
1 day-1.60%
1 week+1.02%
Current month+0.41%
1 month-0.60%
3 months+8.11%
6 months-0.80%
Current year+2.07%
1 week 4.82
Extreme 4.82
5.03
1 month 4.74
Extreme 4.74
5.05
Current year 4.22
Extreme 4.22
5.32
1 year 3.84
Extreme 3.835
5.32
3 years 3.12
Extreme 3.125
5.57
5 years 3.03
Extreme 3.028
10.99
10 years 3.03
Extreme 3.028
10.99
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+1.02% - - 635.29Cr
+2.37%+2.98%+9.31%+86.86% 9.21TCr
+0.51%+0.43%+44.87%+152.61% 5.6TCr
+2.20%+0.72%-7.00%+238.18% 2.23TCr
+1.26%+5.43%-9.79%-27.12% 799.99Cr
+1.90%+13.78%-25.55%-30.74% 776.4Cr
+1.89%+6.02%-9.81%-28.92% 666.05Cr
+0.17%+0.88%-2.15%+21.78% 535.83Cr
+1.86%+6.93%-4.08%-12.79% 362.91Cr
-1.31%+0.76%+13.49%+10.81% 335.77Cr
Average +0.93%+2.53%+1.03%+45.63% 2.28TCr
Weighted average by Cap. +1.54%+2.41%+14.09%+103.86%

Financials

2026 *2027 *
Net sales 2.57TCr 393.96Cr 344.4Cr 316.5Cr 295.02Cr 559.56Cr 38TCr 568.05Cr 3.8TCr 1.48TCr 18TCr 1.48TCr 1.45TCr 64TCr 2.58TCr 395.21Cr 345.49Cr 317.51Cr 295.95Cr 561.34Cr 38TCr 569.85Cr 3.81TCr 1.48TCr 18TCr 1.48TCr 1.45TCr 64TCr
Net income 474.8Cr 73Cr 64Cr 58Cr 54Cr 103.22Cr 6.92TCr 104.79Cr 700.93Cr 272.48Cr 3.4TCr 272.79Cr 266.93Cr 12TCr 483.1Cr 74Cr 65Cr 59Cr 55Cr 105.03Cr 7.04TCr 106.62Cr 713.18Cr 277.25Cr 3.46TCr 277.56Cr 271.6Cr 12TCr
Net Debt 408.94Cr 63Cr 55Cr 50Cr 47Cr 89Cr 5.96TCr 90Cr 603.7Cr 234.69Cr 2.93TCr 234.95Cr 229.91Cr 10TCr -9.36Cr -1.43Cr -1.25Cr -1.15Cr -1.07Cr -2.03Cr -136.38Cr -2.07Cr -14Cr -5.37Cr -67Cr -5.38Cr -5.26Cr -231.01Cr
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
03/26/03 €4.930 -1.60%
02/26/02 €5.010 +2.24%
01/26/01 €4.900 -0.20%
30/26/30 €4.910 +0.61%
29/26/29 €4.880 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
43.12DKK
Average target price
47.46DKK
Spread / Average Target
+10.06%

Quarterly revenue - Rate of surprise